Nextleaf Solutions Awarded U.S. Patent for Synthesizing CBG-O-Acetate

News and research before you hear about it on CNBC and others. Request your one-week free trial of StreetInsider Premium here.

CBG-O-Acetate added to the company’s Specialty Molecules division

Vancouver, British Columbia – (Newsfile Corp. – September 15, 2021) – Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS” or the “Company”), a state-regulated cannabis oil maker that owns one of the largest portfolios of US patents for the extraction and distillation of cannabinoids, is pleased announce that the US Patent and Trademark Office has granted the company a patent for a novel process for acetylating cannabigerol (“CBG”) and then refining CBG-O-acetate.

Acetylation is an organic esterification reaction in which acetic acid is often used. Examples of acetylated pharmaceuticals include aspirin (acetylsalicylic acid) and diacetylmorphine. The company was previously granted US and Canadian patents for the acetylation of CBD and THC and the subsequent refinement of CBD-O-acetate and THC-O-acetate. THC-O-acetate acts as a metabolic prodrug for THC itself and acts chemically just like diacetylmorphine as a metabolic prodrug for morphine.

The company’s latest US patent describes its proprietary manufacturing process for modifying CBG found in cannabis distillate into a prodrug called CBG-O-acetate. As CBG-O-acetate is metabolized in the body, the acetate group is removed, allowing the CBG to interact with the cannabinoid receptors.

“CBG is often referred to as the mother cannabinoid because so many other cannabinoids can be derived from its acidic form,” said Ryan Ko, patent author and chief technology officer of Nextleaf Solutions. “This emission provides further confirmation of our roadmap for the development of specialty molecules.”

The company believes that the CBG-derived prodrug made as part of its patented process may have significant potential as a therapeutic product based on research that CBG may be effective in treating inflammation, pain and nausea . Peer-reviewed studies also suggest that higher doses of CBG may be beneficial in treating conditions such as Crohn’s disease1 and cancer2.

Nextleaf holds 16 issued US patents and over 80 issued patents worldwide for the extraction, purification and dispensing of cannabinoids – the third largest patent portfolio of any cannabis company after Canopy Growth and GW Pharma.

Image 1

To view an improved version of this image, please visit:
https://orders.newsfilecorp.com/files/5347/96599_c509d2cd5442ba21_001full.jpg

“We are very excited to expand our US patent portfolio with this novel production process that, together with our Health Canada licenses, will enable Nextleaf to develop and manufacture truly differentiated cannabinoid-based products through our Specialty Molecules Division,” said Nextleaf Solutions co-founder and CEO Paul Pedersen. “To the best of our knowledge, Nextleaf is the first company in the world – publicly or privately – to be granted patents to manufacture CBG-O-acetate, a specialty molecule that is not legally available anywhere in the world.”

The purpose of the Specialty Molecules Division is to leverage Nextleaf’s existing intellectual property (“IP”) and delivery technology to develop IP-protected therapeutic products made from novel molecules that can provide therapeutic alternatives to opioid-based drugs.

About Nextleaf®

Nextleaf is a government-regulated cannabis oil manufacturer with one of the largest portfolios of US patents for the extraction and distillation of cannabinoids. Nextleaf supplies cannabis oils to its wholesale customers and sells consumer goods under its award-winning Prohibition-Era Glacial Gold brand. “Per day. Nextleaf is developing a delivery technology with sensory assessment of cannabis through human testing under its Health Canada Research License. The company owns 16 US- Patents and has been granted over 80 patents worldwide.

Nextleaf Solutions is traded as OILS on the Canadian Stock Exchange, as OILFF on the OTCQB market in the United States, and as L0MA on the Frankfurt Stock Exchange.

Follow Glacial Gold “on social platforms: Instagram, Twitter and Facebook.
www.glacial.gold

Follow the company on social platforms: Twitter, LinkedIn, Facebook and Instagram.
www.nextleafsolutions.com

For more information, please contact:
Jason McBride, business development
604-283-2301 (ext. 219)
jason@nextleafsolutions.com

On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO

Certain statements in this press release are “forward-looking statements”. All statements that are not historical facts contained in this news release including, but not limited to, the company’s ability to capitalize on its IP portfolio, the company’s strategy, plans, goals, objectives and objectives, and all of them Statements preceded and followed by the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate” “,” estimate, “” forecast, “” forecast, “” project, “” search, “” should “or similar expressions, or the negatives thereof, are forward-looking statements. These statements are not historical facts, but merely represent the company’s expectations, estimates and projections of future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. As a result, actual results could differ materially from what is expressed, implied or projected in such forward-looking statements. Other factors that could cause actual results, performance, or achievements to differ materially include the risk factors discussed in the company’s MD&A for the most recent fiscal year. Management makes forward-looking statements in the belief that they will provide investors with useful information based on their investment objectives and cautions investors not to place undue reliance on forward-looking information. As a result, all forward-looking statements in this press release are limited by these cautionary statements and other warnings or factors contained herein, and no assurance can be given that actual results or developments will be realized or, even if they will materialize, those anticipated Will have consequences for the company. These forward-looking statements speak as of the date of this press release and the company undertakes no obligation to update or revise them to reflect future information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.

1https: //pubmed.ncbi.nlm.nih.gov/23415610/
2https: //pubmed.ncbi.nlm.nih.gov/33562819/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96599

source https://www.bisayanews.com/2021/09/15/nextleaf-solutions-awarded-u-s-patent-for-synthesizing-cbg-o-acetate/